Request Demo
Last update 24 Mar 2025
Fenofibrate/Metformin Hydrochloride
Last update 24 Mar 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Dualtis, Fenofibrate/metformin, Synordia + [2] |
Target |
Action agonists, activators |
Mechanism PPARα agonists(Peroxisome proliferator-activated receptor α agonists), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC4H12ClN5 |
InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N |
CAS Registry1115-70-4 |
View All Structures (2)
Related
4
Clinical Trials associated with Fenofibrate/Metformin HydrochlorideNCT00362323
A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin.
NCT00361868
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia
NCT00349635
A Double-Blind, 3-Arm Study on Weight Loss With a Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Per Day Compared to Metformin 1,700 mg and to Placebo, at 6 Months, in Obese Patients, Followed by: A Double-Blind, 2-Arm Investigation of Weight-Loss Maintenance With the Same Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Compared to Placebo, at 6 Months, in the Responders.
100 Clinical Results associated with Fenofibrate/Metformin Hydrochloride
Login to view more data
100 Translational Medicine associated with Fenofibrate/Metformin Hydrochloride
Login to view more data
100 Patents (Medical) associated with Fenofibrate/Metformin Hydrochloride
Login to view more data
100 Deals associated with Fenofibrate/Metformin Hydrochloride
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dyslipidemias | Phase 3 | Croatia | 01 Jun 2006 | |
| Dyslipidemias | Phase 3 | Finland | 01 Jun 2006 | |
| Dyslipidemias | Phase 3 | France | 01 Jun 2006 | |
| Dyslipidemias | Phase 3 | Germany | 01 Jun 2006 | |
| Dyslipidemias | Phase 3 | Netherlands | 01 Jun 2006 | |
| Dyslipidemias | Phase 3 | Poland | 01 Jun 2006 | |
| Dyslipidemias | Phase 3 | Romania | 01 Jun 2006 | |
| Dyslipidemias | Phase 3 | Ukraine | 01 Jun 2006 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Croatia | 01 Jun 2006 | |
| Diabetes Mellitus, Type 2 | Phase 3 | Finland | 01 Jun 2006 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free